Want to see HK:1255 full AI Analyst Report?
Top Page
TATA Health International Holdings Ltd.
(1255)
Select Model
Select Model
Rating:40Underperform
Price Target:
HK$2.00
â–¼(-0.99% Downside)
Action:N/A
Date:09/23/26
The score is primarily driven by weak financial performance—negative equity, uneven earnings quality, and negative operating/free cash flow in 2025. Technicals add pressure with a below-moving-average setup and negative MACD, while valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Revenue rebound
The return to revenue growth and a partial rebound in 2025 indicate that demand and commercial activity can recover after the prior contraction. If this improvement persists, it could rebuild scale, support operating leverage, and strengthen the company’s ability to fund its business.
Negative Factors
Negative shareholders’ equity
Negative shareholders’ equity signals a severely weakened capital base and limits financial flexibility. It also makes debt-to-equity measures distorted, while leaving fewer internal resources to absorb operating setbacks, support investment, or withstand further losses over the coming periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The return to revenue growth and a partial rebound in 2025 indicate that demand and commercial activity can recover after the prior contraction. If this improvement persists, it could rebuild scale, support operating leverage, and strengthen the company’s ability to fund its business.
Read all positive factors
TATA Health International Holdings Ltd. (1255) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$485.69M
Dividend Yield4.34%
Average Volume (3M)9.73K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth11.34%
EPS Growth82.34%
CountryHK
Employees107
SectorConsumer Cyclical
Sector Strength84
IndustryApparel - Footwear & Accessories
Share Statistics
EPS (TTM)-0.03
Shares Outstanding242,845,000
10 Day Avg. Volume10,400
30 Day Avg. Volume9,733
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-5.80
Price to Sales (P/S)3.16
P/FCF Ratio-14.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TATA Health International Holdings Ltd. Business Overview & Revenue Model
Company Description
TATA Health International Holdings Limited functions as an investment holding company with diverse business interests, including the sale of footwear and healthcare goods, in addition to offering financial and online medical services. Its operatio...
TATA Health International Holdings Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Jun 2025 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 104.96M | 99.80M | 124.45M | 207.54M | 144.61M | 160.93M |
| Gross Profit | 76.40M | 80.26M | 84.95M | 150.76M | 113.94M | 104.72M |
| EBITDA | -6.00M | -20.55M | -39.32M | -33.27M | 18.61M | -49.54M |
| Net Income | -7.54M | 13.35M | -68.34M | -32.29M | 9.61M | -60.76M |
Balance Sheet | ||||||
| Total Assets | 97.41M | 91.12M | 135.19M | 182.11M | 176.05M | 176.86M |
| Cash, Cash Equivalents and Short-Term Investments | 10.43M | 17.92M | 23.00M | 40.00M | 33.65M | 47.03M |
| Total Debt | 32.63M | 25.87M | 35.91M | 54.41M | 51.03M | 52.68M |
| Total Liabilities | 153.26M | 145.56M | 191.37M | 198.28M | 157.12M | 163.26M |
| Stockholders Equity | -55.02M | -54.44M | -64.45M | 1.72M | 33.65M | 23.01M |
Cash Flow | ||||||
| Free Cash Flow | -22.40M | -22.40M | -3.56M | 0.00 | 12.12M | -5.97M |
| Operating Cash Flow | -18.59M | -18.59M | 1.24M | 0.00 | 13.01M | -4.90M |
| Investing Cash Flow | -6.81M | 15.12M | -2.10M | 0.00 | 7.93M | -39.81M |
| Financing Cash Flow | 5.88M | -1.61M | -15.70M | 0.00 | -13.96M | 43.24M |
TATA Health International Holdings Ltd. Technical Analysis
Negative
2.02
Price Trends
2.13
Negative
2.40
Negative
2.01
Negative
Market Momentum
-0.05
Negative
42.73
Neutral
76.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1255, the sentiment is Negative. The current price of 2.02 is above the 20-day moving average (MA) of 2.02, below the 50-day MA of 2.13, and above the 200-day MA of 2.01, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 42.73 is Neutral, neither overbought nor oversold. The STOCH value of 76.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1255.
TATA Health International Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$9.77B | 5.84 | 12.73% | 7.43% | 13.07% | 17.56% | |
75 Outperform | HK$10.11B | 10.30 | 11.35% | 11.24% | 2.33% | -22.20% | |
74 Outperform | HK$593.55M | 5.16 | 11.96% | 6.67% | 1.49% | -9.08% | |
72 Outperform | HK$20.20B | 6.68 | 6.60% | 10.32% | -3.17% | -24.14% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
55 Neutral | HK$2.16B | -672.50 | -0.12% | 63.41% | -7.94% | 99.47% | |
40 Underperform | HK$485.69M | -64.52 | 13.77% | 4.34% | 11.34% | 82.34% |
* Consumer Cyclical Sector Average
HK:1255
TATA Health International Holdings Ltd.
2.00
1.70
566.67%
HK:0210
Daphne International Holdings
0.30
-0.13
-29.58%
HK:1836
Stella International Holdings Limited
12.01
-1.92
-13.75%
HK:1361
361 Degrees International
4.51
-1.08
-19.37%
HK:0551
Yue Yuen Industrial (Holdings)
12.60
0.43
3.52%
HK:1028
C.banner International Holdings Ltd.
0.87
0.67
332.50%
TATA Health International Holdings Ltd. Corporate Events
TATA Health Swings to Interim Loss on Margin Squeeze and Lower Other Gains
Aug 28, 2026
TATA Health International Holdings Ltd. reported interim results for the six months ended 30 June 2026 showing a slight revenue decline to HK$47.3 million from HK$49.5 million and a sharp drop in gross profit as margin fell from 85.3% to 65.5%. Th...
TATA Health Sharply Scales Back Expected Interim Loss After Profit Warning Clarification
Aug 28, 2026
TATA Health International Holdings Ltd. has issued a clarification to its earlier profit warning for the six months ended 30 June 2026, after a post-issuance review of unaudited consolidated financial statements uncovered minor clerical inaccuraci...
TATA Health Issues Profit Warning on Interim Loss After One-Off Gain Falls Away
Aug 27, 2026
TATA Health International Holdings Limited has warned that it expects to report a loss attributable to shareholders of about HK$12.4 million for the six months ended 30 June 2026, compared with a profit of roughly HK$20.6 million a year earlier. T...
TATA Health Faces Winding-Up Petition Over Former Director’s Pay Dispute
Aug 17, 2026
TATA Health International Holdings Ltd. has disclosed that a former independent non-executive director, Tao Chi Keung, has filed a winding-up petition in the Hong Kong High Court over an unpaid director’s emolument claim of HK$139,150.68. Th...
TATA Health Schedules Board Meeting to Review Interim Results and Dividend
Aug 17, 2026
TATA Health International Holdings Limited has scheduled a board meeting for 28 August 2026 to review and approve the unaudited financial results for the six months ended 30 June 2026. The board will also consider the declaration of an interim div...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.